Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Glucagon (GlucaGen)29 residuesHSQGTFTSDYSKYLDSRRAQDFVQWLMNTEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: GlucaGen, Gvoke, Baqsimi
Every insulin-dependent diabetic carries a ticking clock. When blood sugar crashes below consciousness, glucagon is the 29-amino-acid peptide hormone that reverses it, typically within 10 to 15 minutes. Three FDA-approved formulations exist: a traditional reconstitution kit (GlucaGen), a prefilled autoinjector (Gvoke), and a needle-free nasal powder (Baqsimi). The catch is that glucagon only works if the liver still has glycogen to break down. Prolonged fasting, heavy alcohol use, or adrenal insufficiency can deplete those stores entirely. Type 1 and Type 2 diabetics on insulin or sulfonylureas keep a kit on hand as standard emergency preparedness.
Fewer than 50% of caregivers can correctly reconstitute a traditional glucagon emergency kit under simulated stress. That single statistic reshaped the entire product category and drove the development of two newer formulations. Glucagon (CAS 16941-32-5) is a 29-amino-acid peptide hormone produced by pancreatic alpha cells. It is the primary counter-regulatory hormone to insulin. When blood glucose drops to dangerous levels, glucagon binds the glucagon receptor (GCGR) on hepatocytes, triggering a cAMP/protein kinase A cascade that breaks stored glycogen into glucose. Blood sugar typically rises 30 to 100 mg/dL within 10 to 20 minutes of parenteral administration. Three FDA-approved formulations exist today. The traditional GlucaGen kit (Novo Nordisk) requires mixing lyophilized powder with a diluent syringe. Gvoke (Xeris Pharmaceuticals) ships as a room-temperature-stable prefilled autoinjector; no mixing required. Baqsimi (Eli Lilly, approved 2019) is a 3 mg intranasal powder that requires no injection at all. Clinical trials confirmed comparable blood sugar recovery across all three formats. Real-world use is narrow and well-defined. Glucagon is strictly an emergency rescue medication for severe hypoglycemia in patients who can't swallow oral carbohydrates. It also carries an FDA indication as a diagnostic aid for GI radiologic examinations. No off-label wellness or optimization community exists. The diabetes community on Reddit and patient forums tracks this peptide closely, and consensus aligns with the FDA label almost exactly.
Glucagon locks onto the glucagon receptor (GCGR), a class B G protein-coupled receptor sitting on the surface of liver cells. That binding event kicks off a specific intracellular cascade. The receptor activates its stimulatory G-alpha subunit (Gs), which flips on adenylyl cyclase. Adenylyl cyclase converts ATP into cyclic adenosine monophosphate (cAMP). Rising cAMP levels inside the hepatocyte activate protein kinase A (PKA). Two things happen from there. First, PKA phosphorylates phosphorylase kinase, converting it from inactive (b) to active (a) form. Active phosphorylase kinase then phosphorylates glycogen phosphorylase. That enzyme starts cleaving glucose-1-phosphate units off glycogen chains. This process, glycogenolysis, is what physically dumps glucose into the bloodstream. PKA also shuts down glycogen synthase so the liver stops storing glucose and starts releasing it. Second, PKA phosphorylates the transcription factor CREB (cAMP response element-binding protein). CREB turns up expression of gluconeogenic enzymes, specifically phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase). PKA simultaneously dials down glycolysis by reducing pyruvate kinase and phosphofructokinase-2 activity. The net result: blood glucose rises 30 to 100 mg/dL within 10 to 20 minutes of injection [1].
FDA-approved for severe hypoglycemia rescue in diabetics; 29-aa peptide hormone with well-characterized glycogenolysis mechanism; three approved formulations (traditional kit, Gvoke autoinjector, Baqsimi intranasal)
GlucaGen FDA Prescribing Information 2021 (NDA 020918s056); Baqsimi FDA Prescribing Information 2019 (NDA 210134); Gvoke FDA PI 2019 (NDA 210134)
Efficacy requires intact hepatic glycogen stores: fails in prolonged fasting, heavy alcohol use, adrenal insufficiency, or hepatic glycogen depletion; IV dextrose is the only alternative in those cases; not appropriate for any non-emergency chronic use
Universally considered an essential emergency medication for insulin-dependent diabetics; strong consensus to always have a kit on hand; Gvoke preferred by injectors; Baqsimi preferred for caregiver-administered needle-free scenarios
Science and community use case are identical: emergency hypoglycemia rescue only. Community consensus tracks FDA label dosing precisely. No off-label wellness or optimization use exists in the community.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 0.5mg | Single dose |
| Moderate | 1mg | Single dose |
| Aggressive | 1mg | Single dose |
Glucagon isn't something you'll reconstitute at your leisure. If you're using the traditional kit, you're doing it while someone is unconscious and you're panicking. Here's the reconstitution math for the traditional 1 mg kit. The vial contains 1 mg lyophilized glucagon. Inject the full 1 mL of accompanying diluent into the vial. Swirl gently until dissolved (clear, colorless solution). The resulting concentration is 1 mg/mL. For an adult dose (1 mg), draw the full 1 mL, which equals 100 units on a U-100 insulin syringe. For a pediatric dose under 25 kg, draw 0.5 mL (50 units on that same syringe). Use immediately after reconstitution. Do not store reconstituted glucagon. Discard any unused portion. If you're buying a kit for a family member who might need to use it under pressure, consider Gvoke or Baqsimi instead. The traditional kit's multi-step reconstitution fails under emergency conditions more often than most people realize. Store at room temperature (20 to 25 degrees C). Don't refrigerate. Don't freeze. Check your expiration date at every diabetes appointment.
Emergency use only: glucagon is not cycled. Administered as a single rescue dose during episodes of severe hypoglycemia. No ongoing or prophylactic dosing protocol exists.
Emergency rescue medication: no cycling protocol exists or is appropriate. Glucagon is administered once (or twice maximum, 15 min apart) during an acute severe hypoglycemia episode. Prophylactic or scheduled chronic dosing is not indicated and would be potentially harmful.
Or use the universal Peptide Calculator for any peptide.
Expected: Blood glucose begins rising within 5-10 min; most patients regain consciousness within 10-15 min; peak effect ~15-30 min
Monitor: Monitor blood glucose at 15 min; monitor heart rate and blood pressure if patient is on beta-blockers (exaggerated cardiovascular response possible)
Traditional GlucaGen/Glucagon Emergency Kit: Remove the flip-off seal from the vial. Inject the full contents of the diluent syringe (1 mL) into the vial of lyophilized powder. Swirl gently until completely dissolved. Solution should be clear and colorless. If cloudy or particulate, discard it.
Adults and children over 25 kg: draw 1 mL (100 units on a U-100 syringe) for the full 1 mg dose. Children under 25 kg: draw 0.5 mL (50 units) for the 0.5 mg dose.
Inject subcutaneously or intramuscularly into the upper arm, thigh, or buttock. A 25 to 27 gauge needle works for intramuscular. Standard 29 to 31 gauge insulin syringe is fine for subcutaneous. IV is acceptable in clinical settings but not practical for home emergencies.
Gvoke autoinjector or prefilled syringe: No reconstitution needed. Remove cap. Press against outer thigh or abdomen. Activate. Delivers 0.5 mg or 1 mg based on weight. Room-temperature stable.
Press the plunger firmly. That delivers the full 3 mg dose. No inhalation required. Do not reuse the device.
After any formulation: Position the patient on their side to prevent aspiration if vomiting occurs. Once consciousness returns, give 15 to 20g fast-acting oral carbohydrates immediately. Call emergency services regardless of response.
Same formulation, same amount. For Baqsimi, use a new device. IV dextrose is the only alternative if glucagon fails, which points to depleted glycogen stores.
No dose adjustment vs IM; Tmax ~20 min vs ~13 min IM
Upper arm, thigh, or buttock. Half-life ~35-45 min (apparent, reflecting prolonged absorption).
Same dose as SC (0.5 mg or 1 mg); Tmax ~13 min
FDA GlucaGen label apparent t½ = 45 min IM (prolonged absorption from injection site). Gvoke autoinjector is designed for SC use but IM is also acceptable per label.
Same dose (1 mg adult); Tmax immediate; t½ 8-18 min (shortest)
Rapid IV injection (>1 mg) increases vomiting risk significantly. Standard emergency department route. Not practical for home emergency use without IV access.
3 mg IN = 1 mg IM/SC for glycemic response (higher dose compensates for lower bioavailability via nasal route); Tmax ~15 min
Comparable glycemic outcomes to IM/SC in clinical trials. Higher rate of nasal side effects (burning, congestion, watery eyes). No inhalation needed: passive delivery by plunger.
May blunt or completely abolish the hyperglycemic effect of glucagon; mechanism involves inhibition of hepatic cAMP-mediated response
Do not combineExaggerated and potentially prolonged increases in blood pressure and heart rate; glycemic response is preserved but cardiovascular response may be dangerous in patients with coronary artery disease
Glucagon potentiates the anticoagulant effect of warfarin; may increase bleeding risk; monitor INR if glucagon is used in a warfarin patient
Pricing updated 2026-04-09
Nausea hits up to 35% of patients [2]. That makes it the most frequently reported adverse effect. Vomiting usually follows, especially with rapid intravenous doses exceeding 1 mg. Position the patient on their side before administration to prevent aspiration. This isn't optional guidance; it's a real risk when someone is unconscious and about to receive a medication that commonly triggers vomiting. Headache is the other common complaint. Transient spikes in blood pressure and heart rate occur, and this is where the beta-blocker interaction gets dangerous. Patients taking propranolol, metoprolol, or similar drugs can experience exaggerated and prolonged cardiovascular responses. In patients with known coronary artery disease on beta-blockers, the interaction can be clinically serious. Monitor cardiovascular status in those patients. Baqsimi's intranasal route carries its own side effect profile. Users describe the nasal burning as intense. One recurring description in patient reviews across WebMD (n=24 Baqsimi reviews) is "liquid cayenne pepper." Watery eyes, nasal congestion, and upper respiratory tract irritation are reported frequently with the nasal formulation. Injection site reactions (redness, swelling) show up with subcutaneous and intramuscular formulations. These are generally short-lived. The rare but serious risks need their own weight. Generalized allergic reactions and anaphylactic shock (with hypotension and breathing difficulty) are in the literature. They're uncommon, but they exist. Rebound hypoglycemia is the more practically dangerous concern. The glucagon effect wears off within 30 to 60 minutes. If oral carbohydrates aren't given once the patient can swallow, blood sugar will crash again. Community reports on r/diabetes frequently describe this pattern: "thought they were fine and then crashed again." Hypokalemia has been observed in overdose scenarios. The biggest limitation isn't a side effect per se, but a failure mode. Glucagon cannot raise blood sugar if hepatic glycogen stores are depleted. Prolonged fasting, heavy alcohol use, adrenal insufficiency, or chronic hypoglycemia can leave nothing for glucagon to mobilize. The FDA label says to call emergency services regardless of response. Contraindications: pheochromocytoma (risk of catecholamine-driven hypertensive crisis), insulinoma (paradoxical hypoglycemia from stimulated insulin release), glucagonoma (exaggerated hyperglycemia), and hypersensitivity to glucagon or excipients including lactose monohydrate. Pregnancy is FDA Category B with no adequate human studies. Whether glucagon passes into breast milk is unknown.
Verify Glucagon (GlucaGen) dosing and safety with a second opinion
FDA-approved prescription product manufactured under cGMP; dispensed through licensed pharmacies; no compounding market exists or is appropriate for this emergency medication
| Test | When | Target |
|---|---|---|
| Blood glucose | At 15 min post-administration; again at 30-60 min | BG ≥70 mg/dL sustained; if still <70 mg/dL at 15 min, repeat dose and call 911 |
| Blood pressure and heart rate | During and after administration in patients on beta-blockers or with known CAD | — |
Confirm glycemic response; detect failure (glycogen depletion) or rebound hypoglycemia
Glucagon + beta-blockers causes exaggerated and prolonged cardiovascular response; risk of hypertensive episode or arrhythmia in high-risk patients
Glucagon absorbed from injection or nasal mucosa; hepatic signaling cascade initiated
Blood glucose begins to rise as glycogenolysis mobilizes hepatic glucose stores
Most patients regain consciousness; blood glucose typically elevated 30-100 mg/dL above baseline
Peak plasma glucose reached; patient should be given oral carbohydrates to sustain recovery
Glucagon effect waning; risk of rebound hypoglycemia if glycogen stores are depleted
0 to 5 minutes: Glucagon is absorbing from the injection site or nasal mucosa. The GCGR binding event initiates the cAMP cascade in hepatocytes. Glycogenolysis starts at the molecular level. The patient is still unconscious or unresponsive. Nothing visible is happening yet. Caregivers are typically calling 911 during this window. Sweating from the hypoglycemia is ongoing. 5 to 10 minutes: Hepatic glucose output is increasing. Blood glucose climbs at roughly 1 to 2 mg/dL per minute, depending on how much glycogen the liver has stored. Some patients show early stirring. Most are still unconscious. Caregivers sometimes report seeing color return to the patient's face. Nausea may begin as blood glucose rises. 10 to 15 minutes: This is when most patients wake up. Peak plasma glucagon concentration hits around 13 minutes after intramuscular injection [1]. Blood glucose is typically 30 to 100 mg/dL above the pre-treatment low point. The community describes this recovery as "dramatic." Nausea and vomiting affect about 35% of patients. Headache is common. Baqsimi users report nasal burning. 15 to 30 minutes: Peak blood glucose is reached. The patient can swallow now, and oral carbohydrates need to go in immediately. Juice, glucose tablets, anything fast-acting. The patient is alert but fatigued and disoriented. Paramedics are usually on scene. Blood pressure and heart rate may be raised, especially in patients on beta-blockers. 30 to 60 minutes: Glucagon's effect is fading. Plasma concentration is dropping toward baseline. The liver's glycogen stores were partially depleted by the glycogenolysis that saved the patient's life. Without those oral carbohydrates, blood glucose will fall again. Rebound hypoglycemia catches people off guard. Community reports on r/diabetes repeat the same pattern: "thought they were fine and then crashed again."
Glucagon absorbed from injection site or nasal mucosa; GCGR binding initiates cAMP cascade in hepatocytes; glycogenolysis begins
Patient is still unconscious or unresponsive; no visible change yet; caregivers typically calling 911 during this window
Hepatic glucose output increases; blood glucose begins rising at ~1-2 mg/dL per minute depending on glycogen store status
Some patients show early stirring; most still unconscious; some users report seeing color return to patient's face
Peak plasma glucagon ~13 min (IM); blood glucose typically elevated 30-100 mg/dL above pre-treatment nadir; most patients regain consciousness
Strong community consensus: most patients are awake and confused by 10-15 min; community frequently notes the "dramatic" recovery
Peak blood glucose; patient able to swallow; oral carbohydrates should be given immediately to sustain recovery
Patient alert but typically fatigued and disoriented; oral glucose or juice given; paramedics usually arriving
Glucagon plasma concentration returning to baseline; hepatic glycogen stores depleted by the glucagonolysis; without oral carbs, blood glucose will fall again
Community frequently reports surprise second hypoglycemia episode if oral carbs were not given; "thought they were fine and then crashed again" is a common account
Source: Cersosimo et al., Diabetes Care 1985; PMID 3971846: IV t½ 8-18 min; IM ~26 min; SC/IN ~35-45 min
Loading the interactive decay curve.
Glucagon is FDA-approved for two indications: treatment of severe hypoglycemia and as a diagnostic aid during gastrointestinal radiologic examination. All formulations (GlucaGen, Gvoke, Baqsimi, generic Glucagon Emergency Kit) require a prescription. No compounding market exists for glucagon. An emergency rescue medication manufactured under cGMP standards should not be sourced from compounding pharmacies or gray-market vendors. WADA does not list glucagon as a prohibited substance. Athletes with diabetes may carry and use glucagon emergency kits without a Therapeutic Use Exemption for hypoglycemia rescue. Baqsimi received FDA approval in July 2019 as the first nasally administered glucagon. Gvoke received approval in September 2019 as the first room-temperature-stable ready-to-use liquid glucagon. Generic versions of the traditional kit are available from multiple manufacturers. This content is for informational purposes only and does not constitute medical advice. Glucagon is a prescription emergency medication. Consult a healthcare provider for guidance specific to your situation.
Peptide Schedule Research TeamReviewed Apr 20266 Citations
